Customize your JAMA Network experience by selecting one or more topics from the list below.
Shonka DC, Shoushtari AN, Thomas CY, et al. Predicting Residual Neck Disease in Patients With Oropharyngeal Squamous Cell Carcinoma Treated With Radiation Therapy: Utility of p16 Status. Arch Otolaryngol Head Neck Surg. 2009;135(11):1126–1132. doi:10.1001/archoto.2009.153
To identify factors that predict complete response of cervical nodal disease to radiation therapy (RT) in patients with oropharyngeal squamous cell carcinoma (OP-SCCA).
Histologic analysis of prospectively collected specimens and retrospective medical chart review.
Tertiary referral center.
Sixty-nine patients with OP-SCCA treated from January 1, 2002, through June 1, 2008.
Definitive RT, with or without chemotherapy and with or without neck dissection (ND).
Main Outcome Measure
Presence of a viable tumor in post-RT ND specimen.
Tissue specimens from 69 patients with OP-SCCA treated primarily with RT, with or without chemotherapy, were evaluated. Of these, 47 (68.1%) were strongly and diffusely positive for p16 expression by immunohistochemical analysis, signifying human papillomavirus positivity. Patients with p16-positive and p16-negative tumors (hereinafter, p16+ and p16−, respectively) had similarly sized primary tumors on presentation, but p16+ primary tumors were associated with more advanced neck disease (nodal stages N2c-N3; 31.9% vs 4.5% for p16− tumors) and more contralateral nodes (27.7% vs 4.5% for p16− tumors). Forty-seven patients (59.0%) underwent planned posttreatment ND (a total of 55 NDs). The NDs performed for p16− tumors were significantly more likely to have viable tumor in the specimen (50.0% vs 18.0% for p16+ tumors; P = .02). In addition, p16+ necks with residual viable cancer were characterized by incomplete response on post-RT imaging, tobacco and alcohol use, and extracapsular spread on pretreatment imaging.
In conjunction with other clinical parameters, p16 status can help predict the need for post-RT ND in patients with OP-SCCA. Although close observation may be warranted in selected patients with p16+ tumors, patients with p16− tumors are at much higher risk for residual neck disease, even when initial nodal disease is less advanced.
Create a personal account or sign in to: